The Federal Circuit recently issued Rule 36 judgments in two separate BPCIA cases: Genentech v. Amgen and Janssen v. Celltrion. In Genentech v. Amgen, the Federal Circuit affirmed the U.S. District Court for the District of Delaware’s denial of Genentech’s motion for a preliminary injunction to enjoin sales of Amgen’s Kanjinti (trastuzumab-anns) biosimilar product. In part one, Goodwin's IP Litigation lawyers Brian Drummond, and Kline Moore explore some of the unanswered questions raised in Genentech v. Amgen. Read the BioProcess Online byline here.
In The Press August 18, 2020